Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts

European Journal of Haematology

Volumn 73, Issue 5, 2004, Pages 340-350

  Bruserud, Øystein ^a   Wendelbo, Øystein ^a   Paulsen, Kristin ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myelogenous leukemia; Enterococcus faecalis; Leukocytes; Lipoteichoic acid

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; MEMBRANE RECEPTOR; STEM CELL FACTOR; TOLL LIKE RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BLAST TRANSFORMATION; CELL PROLIFERATION; CELL STIMULATION; CYTOKINE RELEASE; DERIVATIZATION; ENTEROCOCCUS FAECALIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEPTOR BINDING; REMISSION; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOCCUS FAECALIS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE PRECURSOR CELLS; HEMATOLOGIC NEOPLASMS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-8; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKOCYTES, MONONUCLEAR; LEUKOPENIA; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES; TEICHOIC ACIDS; TUMOR CELLS, CULTURED;

EID: 5344228231     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00307.x     Document Type: Article

References (38)

1. BRUSERUD Ø, FOSS B, PETERSEN H. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 3 (IL3) and Flt3-ligand (Flt3-L). Eur Cytokine Netw 2001;12:231-238.
2. LÖWENBERG B, DOWNING JR, BURNETT A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-1062.
3. BRUSERUD Ø, HALSTENSEN A, PEEN E, SOLBERG CO. Serum levels of adhesion molecules and cytokines in patients with acute leukaemia. Leuk Lymphoma 1996;23:423-430.
4. CLEVELAND MG, GORHAM JD, MURPHY TL, TUOMANEN E, MURPHY KM. Lipoteichoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway. Infect Immun 1996;64:1906-1912.
5. FISCHER W. Lipoteichoic acid of Bifidobacterium bifidum subspecies pennsylvanicum DSM 20239. A lipoglycan with monoglycerophosphate side chains. Eur J Biochem 1987;165:639-646.
6. FISCHER W. Lipoteichoic acid and lipoglycans, pp. 195-215. In: GHUYSEN JM, HACKENBECK R, eds. Bacterial Cell Wall. Amsterdam: Elsevier Science Publishing, 1994.
7. SUGAWARA S, ARAKAKI R, RIKIISHI H, TAKADA H. Lipoteichoic acid acts as an antagonist and an agonist of lipopolysaccharide on human gingival fibroblasts and monocytes in a CD14-dependent manner. Infect Immun 1999;67:1623-1632.
8. ULEVITCH RJ, TOBIAS PS. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Ann Rev Immunol 1995;13:437-457.
9. WRIGHT SD. CD14 and innate recognition of bacteria. J Immunol 1995;155:6-8.
10. GREENBERG JW, FISCHER W, JOINER KA. Influence of lipoteichoic acid structure on recognition by the macrophage scavenger receptor. Infect Immun 1996;64:3318-3325.
11. OSHIKAWA T, OKAMOTO M, OHE G. et al. Anti-tumor immune responses induced by the fraction derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-γ-inducing activity of OK-432: comparison between the TS-"-binding and TS-2-unbinding fraction. Int Immunopharm 2003;3:643-655.
12. DAWS M, SULLAM PM, NIEMI EC, CHEN TT, TCHAO NK, SEAMAN WE. Pattern recognition by TREM-2: binding of anionic ligands. J Immunol 2003;171:594-599.
13. HRUSAK O, PORWIT-MACDONALD A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia 2002;16:1233-1258.
14. TAKAMATSU Y, MIYAMOTO T, IWASAKI H, MAKINO S, TAMURA K. Remission induction by granulocyte colony-stimulating factor in hypoplastic acute myelogenous leukemia complicated by infection. A case report and review of the literature. Acta Haematol 1998;99:224-230.
15. IHENDYANE N, SPARRELID E, WRETLIND B, et al. Viridans streptococcal septicaemia in neutropenic patients: role of proinflammatory cytokines. Bone Marrow Transplant 2004;33:79-85.
16. OKAMOTO M, OHE G, OSHIKAWA T, NISHIKAWA H, FURIUCHI S, YOSHIDA H, MATSUNO T, SAITO M, SATO M. Induction of Th1-type cytokines by lipoteichoic acid-related preparation isolated from OK-432, a penicillin-killed streptococcal agent. Immunopharmacology 2000;49:363-376.
17. OKAMOTO M, OHE G, FURIUCHI S, et al. Enhancement of antitumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells. Anticancer Res 202;22:3229-3239.
18. VENDITTI M, TARASI A, VISCO COMANDINI U, GENTILE G, GIRMENIA C, MICOZZI A, MARTINO P. Enterococcal septicemia in patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 1993;32:241-247.
19. CHERIF H, KRONVALL G, BJØRKHOLM M, KALIN M. Bacteremia in hospitalized patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-yr period without antibacterial prophylaxis. Hematol J 2003;4:420-426.
20. SPANIK S, TRUPL J, KUNOVA A, et al. Risk factors, aetiology, therapy and outcome in 123 episodes of breakthrough bacteraemia and fungaemia during antimicrobial prophylaxis and therapy in cancer patients. J Med Microbiol 1997;46:517-523.
21. WENDELBO Ø, NESTHUS I, SJO M, ERNST P, BRUSERUD Ø. Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Leukemia Res 2004;28:461-468.
22. LENHOFF S, HJORTH M, HOLMBERG E, et al. Impact on survival on high-dose chemotherapy with autologous stem cell support in patients younger than 60 yr with newly diagnosed multiple myeloma: a population based study. Blood 2000;95:7-11.
23. BRUSERUD Ø, RYNINGEN A, WERGELAND L, GLENJEN NI, GJERTSEN BT. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 2004;89:391-402.
24. BRUSERUD Ø, GJERTSEN BT, von VOLKMAN HL. In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines. J Hematother Stem Cell Res 2000;9:923-932.
25. BRUSERUD Ø, HUANG TS, GLENJEN N, GJERTSEN BT, FOSS B. Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemia blasts. Haematologica 2002;87:584-595.
26. BRUSERUD Ø, HOVLAND R, WERGELAND L, HUANG TS, GJERTSEN BT. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 2003;88:416-428.
27. WENDELBO Ø, BRUSERUD Ø. Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay. J Hematother Stem Cell Res 2003;12:525-535.
28. BRUSERUD Ø, ULVESTAD E. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation. Cell Immunol 2000;206:36-50.
29. WANG JE, JØRGENSEN PF, ALMLØF M, THIEMERMANN C, FOSTER SJ, AASEN AO, SOLBERG R. Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6) and IL10 production in both T cells and monocytes in a human whole blood assay. Infect Immun 2000; 6:3965-3970.
30. STANDIFORD TJ, ARENBERG DA, DANFORTH JM, KUNKEL SL, VAN OTTEREN GM, STRIETER RM. Lipoteichoic acid induces secretion of interleukin-8 from human blood monocytes: a cellular and molecular analysis. Infect Immun 1994;62:119-125.
31. WENDELBO Ø, NESTHUS I, SJO M, PAULSEN K, ERNST P, BRUSERUD Ø. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia. Cancer Immunol Immunother 2004;53:740-747.
32. HARTUNG T, von AULOCK S, FREITAG M, HÖXTERMANN S, STÜCKER M, HOMANN K, ALTMEYER P, KOTTKE A, WENDEL A. Blood cytokine response of low-dose molgrastim (rhGM-CSF)-treated patients. Cytokine 2000;12:1570-1574.
33. BRUSERUD Ø, GJERTSEN BT, BRUSTUGUN OT, BASSØE CF, NESTHUS I, ESPEN AKSELSEN P, BÜHRING HJ, PAWELEC G. Effects of interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. Leukemia 1995;9:1910-1920.
34. SISSOLAK G, HOFFBRAND AV, MEHTA AB, GANESHAGURU K. Effects of interferon (IFN) alpha on the expression of interleukin 1 beta (IL1), interleukin 6 (IL6), granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor alpha (TNF) in acute myeloid leukemia blasts. Leukemia 1992;6:1155-1160.
35. FIEDLER W, SUCIU E, WITTLIEF C, OSTERTAG W, HOSSFELD DK. Mechanisms of growth factor expression in acute myeloid leukemia (AML). Leukemia 1990;4:459-461.
36. MUNKER R, ANDREEFF M. Induction of death (CD95/Fas), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma. Cytokines Mol Ther 1996;2:147-160.
37. HEIL G, KRAUTER J, BEYER-JOHANNBÖKE E, BUNJES D, KURRLE E, WESTPHAL-FROSCH C, HEIMPEL H. CD54 expression and its role in homotypic aggregation of the blasts of acute myeloblastic leukemia. Int J Hematol 1994;60:39-49.
38. GAO JJ, XUE Q, ZUVANICH EG, HAGHI KR, MORRISON DC. Commercial preparations of lipoteichoic acid contain endotoxin that contributes to activation of mouse macrophages in vitro. Infect Immun 2001;69:751-757.